RalA/RalB Antibody (AT41E2) [PE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-88840PE
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Mouse
Applications
ELISA, Flow Cytometry, Western Blot
Label
PE (Excitation = 488 nm, Emission = 575 nm)
Antibody Source
Monoclonal Mouse IgG2b Kappa Clone # AT41E2
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant human RalA/RalB (1-203aa) purified from E. coli
Specificity
Detects both human RalA and RalB protein
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2b Kappa
Applications for RalA/RalB Antibody (AT41E2) [PE]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: RalA/RalB
Long Name
Ras-like Protein A/B
Alternate Names
MGC48949, RAL, Ras family small GTP binding protein RALA, RAS-like protein A, ras-related protein Ral-A, v-ral simian leukemia viral oncogene homolog A (ras related)
Gene Symbol
RALA
Additional RalA/RalB Products
Product Documents for RalA/RalB Antibody (AT41E2) [PE]
Product Specific Notices for RalA/RalB Antibody (AT41E2) [PE]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...